SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation is a research paper published in Diabetes (2020). On theSindex it has a DataRank of 0. It has been cited 124 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Steno Diabetes Center Copenhagen (SDCC)
Grant: SDCC 3.A Complications
FWCI
9.77
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
Additional file 1 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
Additional file 2 of Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study
Additional file 1 of Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study
Additional file 1 of Cardiovascular benefits of SGLT2 inhibitors in type 2 diabetes, interaction with metformin and role of erythrocytosis: a self-controlled case series study
Additional file 1 of Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort
Additional file 1 of Rapid kidney function decline and increased risk of heart failure in patients with type 2 diabetes: findings from the ACCORD cohort
Additional file 1 of Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)
Additional file 1 of Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)
Additional file 2 of Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)
Additional file 2 of Rationale and study design of a randomized controlled trial to investigate the renoprotective effect of canagliflozin assessed by test of renal hemodynamics in diabetic kidney disease (the FAGOTTO study)